Exploring cannabidiol, cannabis use disorder, withdrawal symptoms, clinical trials and the scientific evidence for CBD as a potential treatment.
Cannabis is widely used around the world, but regular or prolonged use can lead some individuals to develop cannabis use disorder (CUD), a condition involving difficulty controlling cannabis consumption despite negative consequences.
For people attempting to reduce or stop cannabis use, withdrawal symptoms, cravings and established behavioural patterns can make the process challenging.
Researchers have investigated whether cannabidiol (CBD), a non-intoxicating constituent of cannabis, could help reduce cannabis consumption and support treatment for cannabis use disorder.
Importantly, this is more than a theoretical question. Human clinical trials have investigated CBD for this purpose, with some reporting promising results.
However, the findings require careful interpretation, particularly when distinguishing purified CBD used in clinical research from commercially available full-spectrum cannabinoid preparations.
Understanding Cannabis Use Disorder (CUD)
Cannabis use disorder is characterised by a problematic pattern of cannabis consumption that causes significant impairment or distress.
It may involve symptoms such as:
Difficulty reducing or controlling cannabis use.
Repeated unsuccessful attempts to stop.
Continued use despite adverse consequences.
Spending considerable time obtaining, using or recovering from cannabis.
Cravings or strong urges to use cannabis.
Withdrawal symptoms when consumption is reduced.
Increasing tolerance in some individuals.
The likelihood of developing cannabis use disorder is influenced by several factors, including frequency of use, age of initiation, product potency and individual susceptibility.
Not everyone who consumes cannabis develops a disorder, but dependence and withdrawal are well-documented clinical phenomena.
Challenges of Quitting Cannabis
People who regularly consume cannabis may experience withdrawal symptoms when they reduce or stop using it.
Commonly reported symptoms include:
Irritability and changes in mood.
Anxiety and restlessness.
Difficulty sleeping.
Changes in appetite.
Cravings for cannabis.
Physical discomfort, including headaches or abdominal symptoms in some individuals.
Withdrawal symptoms can make abstinence difficult, particularly when cannabis has become associated with sleep, relaxation or relief from distress.
These challenges have encouraged researchers to investigate pharmacological and psychological approaches to treatment.
CBD is among the compounds being studied.
What Is CBD?
Cannabidiol is a naturally occurring phytocannabinoid found in Cannabis sativa.
Unlike tetrahydrocannabinol (THC), CBD does not ordinarily produce the characteristic cannabis intoxication associated with THC.
CBD has complex pharmacological actions involving several biological pathways, including those related to endocannabinoid signalling, serotonin receptors and neuronal activity.
These properties have prompted investigations into its possible role in substance use disorders.
However, CBD should not be assumed to act as a straightforward blocker or activator of CB1 and CB2 receptors.
Its pharmacology is more complex, and potential effects on addiction-related behaviour may involve multiple neural processes.
What Does Clinical Research Reveal About CBD and Cannabis Dependence?
1. The Lancet Psychiatry Clinical Trial
One of the most important investigations was published by Freeman and colleagues in The Lancet Psychiatry in 2020. [1]
The researchers conducted a phase 2a, double-blind, placebo-controlled, randomised trial involving 82 participants diagnosed with cannabis use disorder.
The study examined three daily doses of oral CBD:
200 mg.
400 mg.
800 mg.
Participants received CBD or placebo during a four-week attempt to stop using cannabis, alongside a brief psychological intervention.
The study used an adaptive Bayesian design, allowing researchers to discontinue doses that appeared unlikely to be effective.
What Did the Researchers Find?
The 200 mg daily dose was eliminated during the trial because it did not meet the criteria for sufficient efficacy.
Both 400 mg and 800 mg daily CBD demonstrated evidence of benefit compared with placebo.
For the 400 mg group, investigators reported a reduction in the urine THC-COOH-to-creatinine ratio, a biological measure associated with cannabis exposure.
The same group also recorded approximately 0.48 additional cannabis-abstinent days per week compared with placebo.
The 800 mg group likewise showed evidence of reduced cannabis use.
CBD was generally well tolerated during the study.
Why This Study Matters
This was a controlled human investigation using objective and self-reported measures of cannabis consumption.
Its results provide meaningful evidence that CBD may have a role in reducing cannabis use among people with cannabis use disorder.
Nevertheless, the study was relatively small and designed to identify promising doses rather than definitively establish a long-term treatment.
It also investigated purified CBD under clinical conditions.
The findings therefore cannot automatically be applied to lower-dose commercial products or full-spectrum cannabis extracts.
The doses were experimental research doses, not general recommendations for self-treatment.
2. The Cannavap Pilot Study: Inhaled CBD
A separate investigation published in Frontiers in Psychiatry in 2022 examined inhaled CBD in people with cannabis use disorder. [2]
Known as the Cannavap study, it explored the feasibility and potential effects of administering CBD through an inhalation device.
Twenty participants were enrolled.
Researchers monitored cannabis consumption, withdrawal symptoms, cravings and related outcomes.
Some participants experienced encouraging changes in cannabis-related behaviours.
However, only nine participants completed the follow-up assessment.
Interpreting the Findings
The study was exploratory and did not include a randomised placebo-controlled comparison.
Consequently, improvements could not be confidently attributed to CBD itself.
Other factors, including participant motivation, changes in circumstances and treatment engagement, may have contributed.
The investigators concluded that a properly controlled clinical trial would be necessary to establish efficacy.
The study remains scientifically relevant because it explored a different route of CBD administration, but its findings should not be treated as confirmation of an effective withdrawal treatment.
3. CBD and Cannabis Use: A Published Case Report
A case report published by Shannon and Opila-Lehman described a 27-year-old man with bipolar disorder and longstanding problematic cannabis use. [3]
The patient received CBD oil as an addition to his existing treatment.
The report described reductions in cannabis use alongside improvements in certain anxiety and sleep-related symptoms.
The CBD dosage decreased from approximately 24 mg to 18 mg during the reported intervention.
What Can a Case Report Establish?
Case reports can provide valuable clinical observations.
They may reveal unexpected outcomes, generate hypotheses and identify subjects worthy of further investigation.
However, a single case report cannot determine whether a treatment caused an observed improvement.
Without a control group, it is difficult to exclude alternative explanations, such as changes in motivation, behavioural patterns or other circumstances.
The report therefore supports further investigation, rather than establishing CBD as an effective treatment for cannabis dependence.
4. CBD and the Brain's Reward System
Addiction involves several interconnected biological processes.
These include reward-related learning, motivation, stress responses, habit formation and neural adaptations associated with repeated substance exposure.
Dopamine signalling is one important component, but it is not the only mechanism involved.
Researchers have investigated whether CBD influences pathways relevant to substance-seeking behaviour.
A 2015 article in Neurotherapeutics reviewed CBD's potential role in addiction research, with particular attention to opioid relapse. [4]
The authors discussed early evidence suggesting that CBD could influence drug-seeking behaviour under certain experimental conditions.
The review also emphasised that evidence remained insufficient to establish CBD's effectiveness across different substance use disorders.
Relevance to Cannabis Dependence
Findings involving opioid-seeking behaviour do not automatically demonstrate equivalent effects on cannabis cravings.
Different substances produce different adaptations within neural reward and stress systems.
Nevertheless, studying CBD's interactions with these pathways provides a scientific rationale for investigating its potential applications in cannabis use disorder.
Can CBD Reduce Cannabis Withdrawal Symptoms?
An important distinction exists between reducing cannabis consumption and directly treating withdrawal symptoms.
The Freeman clinical trial provided evidence concerning cannabis-use outcomes, including biological measures and abstinent days. [1]
However, those findings do not automatically establish that CBD reliably relieves every component of withdrawal.
The Cannavap pilot examined withdrawal-related experiences but lacked the controlled design needed to establish causation. [2]
The case report described improvements in one patient, but such observations cannot be generalised confidently. [3]
At present, the evidence suggests that CBD deserves further investigation for cannabis withdrawal, especially regarding:
Anxiety and irritability.
Craving intensity.
Sleep disturbance.
Withdrawal-related discomfort.
Risk of resuming cannabis use.
Larger, controlled studies are required to determine which symptoms, if any, respond reliably to defined CBD preparations.
CBD, Anxiety and Stress During Cannabis Cessation
Anxiety and stress can complicate attempts to stop using cannabis.
Some individuals may have used cannabis partly to manage distress, while others experience anxiety as a consequence of withdrawal.
CBD has independently been investigated for its effects on anxiety-related processes.
Some controlled human experiments have reported reductions in experimentally induced anxiety.
These findings provide a possible rationale for investigating whether CBD could support people experiencing anxiety during cannabis cessation.
However, evidence from anxiety research cannot automatically establish that CBD reduces cannabis withdrawal or prevents relapse.
Those outcomes require specific clinical trials involving people with cannabis use disorder.
CBD and Sleep During Cannabis Withdrawal
Sleep disturbance is common during cannabis withdrawal.
People may experience difficulty falling asleep, frequent waking or changes in dreaming.
Researchers have investigated CBD in relation to sleep, but clinical findings have been mixed.
Some studies have reported improvements in selected outcomes, while others have found limited or no advantage over placebo.
The evidence does not yet establish that CBD reliably corrects sleep disturbances associated with cannabis withdrawal.
It is therefore important to distinguish general sleep research from studies directly examining sleep during cannabis cessation.
Does CBD Reduce Cannabis Cravings?
Craving is an important feature of many substance use disorders.
It can involve both conscious urges to consume a substance and responses triggered by environments, emotions or learned associations.
Preclinical research suggests that CBD may influence certain processes involved in drug-seeking behaviour. [4]
Clinical studies involving cannabis use disorder have also investigated consumption and abstinence outcomes.
However, reducing cannabis consumption is not identical to demonstrating a direct effect on craving.
Further research is needed to clarify whether CBD specifically reduces cannabis cravings, whether any effect is dose-dependent and whether it persists after treatment ends.
CBD Isolate, Broad-Spectrum and Full-Spectrum Preparations
The formulation used in a study is particularly important.
CBD Isolate
CBD isolate consists predominantly of purified cannabidiol.
Purified CBD preparations are useful in clinical trials because researchers can more precisely investigate the effects of CBD without substantial contributions from other cannabinoids.
Broad-Spectrum Extracts
Broad-spectrum preparations may contain multiple cannabinoids and other plant compounds while being formulated to exclude THC.
Their precise composition varies.
Full-Spectrum Extracts
Full-spectrum extracts contain CBD alongside additional naturally occurring constituents, potentially including THC.
Researchers have investigated possible interactions between cannabinoids and terpenes, sometimes described as the entourage effect.
However, the presence of additional constituents does not automatically establish enhanced treatment effects.
This distinction matters particularly in cannabis use disorder.
A CBD trial involving a highly purified preparation cannot establish that a full-spectrum product containing THC will produce the same outcomes.
Product composition and potential THC exposure are relevant considerations when investigating treatment for cannabis dependence.
What About Dosage?
Clinical studies have investigated markedly different CBD dosages.
The Freeman trial examined 200 mg, 400 mg and 800 mg daily, identifying 400 mg and 800 mg as promising within its particular design. [1]
The case report described much lower doses in an individual patient. [3]
These differences demonstrate why dosage cannot be inferred from a single study.
Research doses depend on the preparation, study objectives, participant population and clinical supervision.
The results do not establish a universal dosing regimen for people wishing to stop cannabis use.
CBD may also interact with prescription medications and can produce adverse effects.
Individuals seeking treatment for cannabis use disorder should obtain advice from appropriately qualified healthcare professionals rather than treating experimental research doses as self-administration instructions.
Psychological and Behavioural Approaches
CBD research should be considered alongside established treatment approaches for cannabis use disorder.
Psychological interventions have been investigated extensively.
A Cochrane review of psychosocial treatments examined approaches including:
Cognitive behavioural therapy (CBT).
Motivational enhancement therapy (MET).
Motivational interviewing.
Contingency management.
Other structured psychological and behavioural interventions.
The review found evidence that these approaches could reduce cannabis use, particularly in the shorter term. [5]
Later evidence reviews have continued to examine the effectiveness of these interventions.
These approaches address behavioural, psychological and environmental factors that medication alone may not resolve.
Importantly, the Freeman CBD trial included a psychological intervention alongside the study medication.
It would therefore be inaccurate to interpret its findings as evidence that CBD alone was responsible for every aspect of participants' treatment progress.
Is CBD an Established Treatment for Cannabis Use Disorder?
The evidence is promising but not yet definitive.
The 2020 randomised trial demonstrated measurable improvements in cannabis-use outcomes at particular CBD doses. [1]
A 2022 systematic review of randomised cannabinoid trials examined the broader evidence for treating cannabis use disorder. [6]
The review highlighted the need for more robust investigations to determine the effectiveness and safety of cannabinoid-based interventions.
The available findings support continued clinical research, but they do not establish that CBD is a universally effective or routinely approved treatment for cannabis dependence.
Questions remain concerning:
Long-term abstinence.
Relapse prevention.
Treatment duration.
Optimal formulation.
Dose-response relationships.
Withdrawal symptom relief.
Interactions with psychological treatment.
Safety in different patient populations.
What Does the Research Tell Us?
The evidence supports several important conclusions.
First, cannabis use disorder is a recognised clinical condition, and withdrawal symptoms can make cessation difficult.
Second, CBD has pharmacological properties that justify scientific investigation in addiction research.
Third, a randomised controlled trial involving 82 participants reported promising reductions in cannabis use with specific daily doses of purified CBD.
Fourth, smaller exploratory studies and case reports provide additional observations, but their designs limit the conclusions that can be drawn.
Finally, existing research does not establish that every CBD oil or full-spectrum preparation provides effective treatment for cannabis dependence.
Final Thoughts
CBD and cannabis use disorder represent an important and developing area of scientific research.
The 2020 clinical trial by Freeman and colleagues provided encouraging evidence that purified CBD may reduce cannabis consumption under controlled conditions.
Additional research has explored withdrawal, craving, sleep and addiction-related biological pathways.
At the same time, significant questions remain regarding long-term outcomes, formulation differences, individual responses and the integration of CBD with established treatment approaches.
CBD's potential role in cannabis use disorder is supported by genuine clinical investigation, but its clinical applications require further confirmation.
Accurately understanding these findings helps distinguish promising research from treatment conclusions that have not yet been established.
Scientific References
[1] Freeman, T. P., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), 865–874.
https://doi.org/10.1016/S2215-0366(20)30290-X
[2] Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap. (2022). Frontiers in Psychiatry, 13, 899221.
https://doi.org/10.3389/fpsyt.2022.899221
[3] Shannon, S., & Opila-Lehman, J. (2015). Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integrative Medicine, 14(6), 31–35.
https://pubmed.ncbi.nlm.nih.gov/26807069/
[4] Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. (2015). Neurotherapeutics, 12, 807–815.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4604178/
[5] Psychosocial Interventions for Cannabis Use Disorder. (2016). Cochrane Database of Systematic Reviews.
https://www.cochrane.org/evidence/CD005336_psychosocial-interventions-cannabis-use-disorder
[6] Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials. (2022).
https://pmc.ncbi.nlm.nih.gov/articles/PMC9256935/
This article examines published scientific research for educational purposes. Clinical results involving specific CBD preparations and research doses should not be applied indiscriminately to commercial cannabinoid products. Individuals experiencing problematic cannabis use should seek appropriate professional advice.
Join the conversation
Comments
Have a question or something to share? We'd love to hear from you.